Feb 27 (Reuters) - Maia Biotechnology Inc MAIA.A:
MAIA BIOTECHNOLOGY INC: LANS TO INITIATE A PHASE 3 PIVOTAL TRIAL IN 2025, NAMED THIO-104
MAIA BIOTECHNOLOGY EXPECTS TO BEGIN ENROLLING PATIENTS IN THIO-104 IN SECOND HALF OF 2025 IN SELECT COUNTRIES IN ASIA, EUROPE, U.S
Source text: [ID:n0001493152-25-008540]
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.